Self-reported information on joint replacement and cholecystectomy agrees well with that in medical records

OBJECTIVES: To examine the validity of self-reported primary hip replacement, primary knee replacement, and cholecystectomy. STUDY DESIGN AND SETTING: The data from 28,524 participants in the Million Women Study who were recruited from Scotland were linked with routinely collected Scottish hospital admission data. We compared the reporting of three operations by the study participants on a postal questionnaire with that recorded in the hospital admission database. RESULTS: Annual incidence rates for the three operations were similar using hospital admission and self-reported data at: 2.1 (n=220) and 2.3 (n=247) per 1,000 women, respectively, for hip replacement; 1.1 per 1,000 women from both sources for knee replacement (n=118 and n=116, respectively); and 3.4 (n=357) and 3.2 (n=344) per 1,000 women, respectively, for cholecystectomy. Agreement between self-report and the hospital admission records was good for all three operations with agreements of 99.8%, 99.9%, and 99.6% for hip replacement, knee replacement, and cholecystectomy, respectively. CONCLUSION: In middle-aged women who answered postal questionnaires, self-reporting of primary hip replacement, primary knee replacement, and cholecystectomy was found to agree well with information held in a medical record database.     

The effect of rosuvastatin treatment on the mean platelet volume in patients with uncontrolled primary dyslipidemia with hypolipidemic diet treatment

Platelet activation and aggregation are central processes in the pathophysiology of coronary heart disease. Mean platelet volume (MPV), a determinant of platelet activation, is a newly emerging risk marker for atherothrombosis. Rosuvastatin, a new hydrophilic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin), is approved as an adjunct to diet in patients with dyslipidemia. In this study, we evaluated the effects of rosuvastatin on the MPV levels in patients with uncontrolled primary dyslipidemia with hypolipidemic treatment. We selected 30 age, sex and body mass index matched patients with uncontrolled primary dyslipidemia and hypolipidemic diet treatment and 30 normolipidemic healthy subjects. Dyslipidemic patients were treated with 10 mg/day rosuvastatin for 12 weeks. Metabolic parameters and MPV were measured at baseline and after rosuvastatin treatment in dyslipidemic group. At baseline, the dyslipidemic group had significantly higher MPV levels than in the healthy control group (8.4 +/-1.2 fl vs. 8.1 +/-0 1.0 fl, p < 0.005). The level of MPV decreased significantly after rosuvastatin treatment from a mean of 8.4 +/- 1.2 fl to 8.1 +/- 1.3 fl, (p < 0.001). The changes in MPV levels with rosuvastatin treatment were not correlated to changes in plasma lipids (p > 0.05). In addition to its well-known hypolipidemic effect, rosuvastatin also possesses significant anti-platelet activation properties. This antiplatelet effect of rosuvastatin treatment could play a role in reducing cardiovascular complications in primary hyperlipidemic patients.     

Optimum mesh and port sizes for laparoscopic incisional hernia repair

PURPOSE: Since incisional hernia repair was introduced into laparoscopic surgical practice it has been recognized that larger meshes can be problematic to successfully insert through laparoscopic ports. This study aims to facilitate the choice of mesh and port by documenting the minimum port sizes realistically needed for insertion of different types and sizes of onlay mesh. It also aims to evaluate the optimal insertion techniques. MATERIALS AND METHODS: Using four specified insertion techniques--simple roll, a tight roll along the longest edge; diagonal roll, a tight roll along the longest axis; roll and bind, the optimal roll with an additional vicryl tie as binding; and unprepared, grasped by the corner, the diagonal length of the mesh is presented head-on to the port--two independent investigators attempted insertion of different sizes of four onlay meshes--DualMesh (1 mm and 1.5 mm), Surgisis Gold, and Permacol--down 10- to 18-mm Endopath and Versaport ports positioned within a sham abdomen. The maximum mesh sizes used were DualMesh, 34 x 26 cm; Surgisis Gold, 22 x 13 cm; and Permacol, 10 x 10 cm. Two types of ports were used, Endopath ports which have an integral seal and Versaport ports with a removable seal. RESULTS: The largest mesh widths successfully passed down 18-, 12-, 11-, and 10-mm ports, respectively, were: DualMesh 1 mm--26, 17, 15, and 13 cm; Surgisis Gold--13, 13, 13, and 10 cm; DualMesh 1.5 mm--26, 15, 12, and 9 cm; and Permacol--10, 10, 10, and 7 cm. The novel roll and bind insertion technique showed improved insertion than the simple roll technique alone for the biological meshes. CONCLUSION: Small differences in mesh size and type can lead to marked changes in optimal port size. The availability of a guide such as the one produced by this study in the operating room will help surgeons to plan and select appropriate combinations of ports and meshes, potentially reducing intraoperative delays.     

Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies

Tobacco smoking has been classified as a cause of cervical cancer, but the effect of different patterns of smoking on risk is unclear. The International Collaboration of Epidemiological Studies of Cervical Cancer has brought together and combined individual data on 13,541 women with and 23,017 women without cervical carcinoma, from 23 epidemiological studies. Relative risks (RRs) and 95% confidence intervals (CIs) of carcinoma of the cervix in relation to tobacco smoking were calculated with stratification by study, age, sexual partners, age at first intercourse, oral contraceptive use and parity. Current smokers had a significantly increased risk of squamous cell carcinoma of the cervix compared to never smokers (RR = 1.60 (95% CI: 1.48-1.73), p<0.001). There was increased risk for past smokers also, though to a lesser extent (RR = 1.12 (1.01-1.25)), and there was no clear trend with time since stopping smoking (p-trend = 0.6). There was no association between smoking and adenocarcinoma of the cervix (RR = 0.89 (0.74-1.06) and 0.89 (0.72-1.10) for current and past smokers respectively), and the differences between the RRs for smoking and squamous cell and adenocarcinoma were statistically significant (current smoking p<0.001 and past smoking p = 0.01). In current smokers, the RR of squamous cell carcinoma increased with increasing number of cigarettes smoked per day and also with younger age at starting smoking (p<0.001 for each trend), but not with duration of smoking (p-trend = 0.3). Eight of the studies had tested women for cervical HPV-DNA, and in analyses restricted to women who tested positive, there was a significantly increased risk in current compared to never smokers for squamous cell carcinoma (RR = 1.95 (1.43-2.65)), but not for adenocarcinoma (RR = 1.06 (0.14-7.96)). In summary, smokers are at an increased risk of squamous cell but not of adenocarcinoma of the cervix. The risk of squamous cell carcinoma increases in current smokers with the number of cigarettes smoked per day and with younger age at starting smoking.